Despite losing nearly identical weight to Sarah, her body composition was poor
Karl D, Philis-Tsimikas A, Darsow T, et al
Current GLP-1 therapies have transformed obesity care, but challenges around GI side effects, lengthy titration schedules, adherence, and patient persistence remain significant barriers for many patients
Investigating the same primary endpoint, TRANSCEND-T2D-2 (NCT06260722) will compare retatrutide to semaglutide in people with inadequately controlled T2D (treated with oral glucose-lowering treatments) over 26 months
Many clients note changing eating habits: wanting lighter food, less sweets, less "eating from boredom." Average weight loss 5-8% of initial weight in first 3 months
This leads to lower calorie consumption and better control over eating habits